Cabaletta Bio’s Post

Years of clinical trials have solidified EKOS™ as the preferred interventional treatment for acute, intermediate-high risk PE cases. Prof. Kucher, Dr. Sterling, and Prof. Konstantinides discuss how it all started with EKOS including the very first RCT to compare an interventional therapy - EKOS vs anti-coagulation. Simple, Safe, Studied

Survodutide (GLP1RA/GCGRA) achieves primary endpoint in Ph2 clinical trial. -- Top-line result: ➡ 83% improvement in biopsy-proven MASH❗ https://lnkd.in/gEGRe5vH

Join us in honoring all the researchers, clinicians, and trial participants who contribute to the advancement of medicine on this #ClinicalTrialsDay. Your tireless efforts bring us one step closer to a healthier future. Our DurAVR™ THV First-in-Human and Early Feasibility Study clinical trials have allowed us to continuously refine and improve our transcatheter heart valve system to treat patients with aortic stenosis. We are rigorously testing our products and preparing for a larger pivotal clinical trial poised to lead to market approval. Learn more about our current clinical data here: https://lnkd.in/gvMsnjRM Christopher Meduri, Anita Asgar, Azeem Latib, Edwin Ho, Andreas Scotti, Stanley Chetcuti, Gorav Ailawadi, MD, MBA, P Michael Grossman, Sinichi Fukuhara, Maia Zhividze, Rishi Puri, Thomas E. Waggoner, DO, FACC, FSCAI, FSVM, RPVI, Vinayak Bapat, Tamaz Shaburishvili, Teona Zirakashvili

The EffPac trial was a prospective, multicentre, randomised controlled trial (RCT) that enrolled 171 patients of Rutherford category two to four with medium-length femoropopliteal lesions. Patients were allocated 1:1 to either Luminor drug-coated balloon (DCB) angioplasty or plain balloon angioplasty (POBA). The long-term results showed a high efficacy (fTLR 82.1%) and statistically superior primary patency for Luminor over POBA, and importantly, showed that DCB use resulted in no safety differences between the two groups. The investigators achieved on-site patient visits in 50% of the recruited patients after five years. “These data are pretty rare […] and actually after this whole discussion about safety of paclitaxel-coated DCBs, I think [this trial] really adds important data,” Prof. Dr. Ulf Teichgräber (Jena, Germany) tells Vascular News at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2023 annual meeting. This video is sponsored by iVascular. https://lnkd.in/e6_NEXm7 #EffPac #DCB #femoropoplitea #endovascular

Yesterday, our CEO, Frederic Cren; CMO, Dr. Michael Cooreman; and Dr. Stephen Harrison, Medical Director for Pinnacle Clinical Research, shared key insights on the latest developments of lanifibranor in #MASH/ #NASH treatment. Learn more about the positive results of LEGEND Phase IIa combination trial with #lanifibranor and empagliflozin for MASH/NASH and #T2D patients: https://lnkd.in/ejxiZj6s

#HappeningNow: In partnership with Incyte, we’re presenting the full results from our AGAVE-201 pivotal trial of axatilimab in patients with chronic GVHD during American Society of Hematology’s #ASH23 Plenary Scientific Session.   We believe that the additional positive data from AGAVE-201 further strengthen axatilimab’s strong safety and efficacy profile as a well-differentiated treatment option for patients with refractory chronic GVHD.   Read the full press release and view the additional data here:  https://bit.ly/3RBczCQ

🫀 Treating In-Stent Restenosis 🫀 13 October, 17:05 - 17:50 CEST ✅ Explore thrombosis, in-stent stenosis, and IVUS. ✅ Learn Jetstream's effectiveness, safe in-stent techniques, and IVUS benefits. ✅ How do patients reach the Lab in the Acute Phase? ✅ Why and how to treat patients with Acute DVT using AngioJet™ Register now ➡️ https://ow.ly/z28650PUy3z This breakout is supported by Boston Scientific. #VIO2023

What are the current management options, algorithms and recommendations for treatment of myeloid blast phase CML? Gain insights into this rare condition’s progression, as Professor Mhairi Copland summarises recent studies and clinical trials, and explores combination therapies and novel therapy options that are currently being assessed. Learn more about Myeloid-BP CML in the iCMLf Knowledge Centre here: https://bit.ly/47CsCX4

#AFDD is a wrap 🙌 Amazing touching base with all our great clients and collaborators and even meeting up with new clients to discuss interesting projects. Happy for the great reception of our BLEO-IPF mouse model, already being called “golden standard” by our clients 🙌 Uniquely, we apply plethysmography for confirming lung deficit at baseline and spirometry-validated lung dysfunction including clinical endpoint analysis (FVC) at study end. In addition histopathological Ascroft scoring using GHOST, supported by quantitative histological markers for inflammation and fibrosis/fibrogenesis. Did you miss our poster with benchmark ALK5i in BLEO-IPF model? Or our characterization data in BLEO-IPF model? Below find links: https://lnkd.in/dX5pnv5s https://lnkd.in/efB_qsDi After travelling Seoul-Boston-Copenhagen, I am now gonna recover a little and reset my circadian clock 🤩 See you then at #AASLD in two weeks 👌

🚨 Missed the live Tweetorial by Dr Paolo Tarantino No worries! You can now watch the on-demand video here: https://lnkd.in/dBPp7QHf Join Dr Tarantino as he journeys through a ER+/HER2- #mBC patient case and explores the diagnostic and treatment processes including: 🔸When and how to use molecular testing to tailor treatment strategies 🔸2nd line treatment options for ER+ MBC 🔸The current data on oral SERDs as monotherapy and in combination therapy #MedEd #bcsm